Kristine Mykulowycz

University of Pennsylvania — United States

Medicine · Health Sciences

5h-index294citations9works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(4), Cholangiocarcinoma and Gallbladder Cancer Studies(4), Hepatocellular Carcinoma Treatment and Prognosis(3), Gastric Cancer Management and Outcomes(3), Cancer Treatment and Pharmacology(3)

Publications9 total

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
British Journal of Cancer·2015· 23 citedOpen Access
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
Annals of Oncology·2013· 89 citedOpen Access
Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors.
Journal of Clinical Oncology·2013· 7 cited
A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report.
Journal of Clinical Oncology·2012· 1 cited
An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study.
Journal of Clinical Oncology·2012
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
Cancer·2011· 97 citedOpen Access
Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study.
Journal of Clinical Oncology·2010· 1 cited
Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study
Journal of Clinical Oncology·2007· 72 cited
A phase II trial of combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): Preliminary safety analysis
Journal of Clinical Oncology·2006· 4 cited

Frequent Co-authors

Bruce J. Giantonio(8), Weijing Sun(6), Ursina Teitelbaum(5), Paul Wissel(5), Davendra Sohal(4), Daniel G. Haller(4), Peter J. O’Dwyer(4), Nevena Damjanov(4), Mary Carberry(4), Michael C. Soulen(3), Kim M. Olthoff(3), Mona Jacobs-Small(3), Mark Rosen(2), Millie Caparro(2), Takeshi Uehara(2), Antonia R. Sepulveda(2), Bojana Milojkovic Kerklaan(2), Martijn P. Lolkema(2), Lot A. Devriese(2), Emile E. Voest(2)